Good reason to drink more Coffee

Good reason to drink more Coffee

Everyone thinks caffeine but more specifically coffee is unhealthy for you but in relation to nonalcoholic fatty liver (NAFL) disease it can be beneficial. You may think that since soda has caffeine in it that you should drink lots of Coke or other products to reduce the effects of NAFL but you are wrong. Soda has a lot of chemicals and artificial sweeteners in it that will cause the effects of NAFL to increase. Sadly, the great taste of these sodas doesn’t make up for the problems it causes. Thankfully, all-natural black coffee does not have all these harmful chemicals that sodas include. That is why consumption of caffeine in coffee is much safer and healthier for you. Caffeine consumption has been known to reduce hepatic fibrosis with chronic liver disease. There have been some studies to support this conclusion. Caffeine consumption is not directly related to the prevalence of hepatic fibrosis. However, daily coffee caffeine may reduce hepatic fibrosis in patients. Most of the US population consume caffeine daily. Coffee is the main source of caffeine and has been consistently increasing over the years. Some studies suggest that coffee consumption decrease the effects of some diseases, such as hepatitis C virus, nonalcoholic fatty liver disease, and diabetes mellitus type 2. A simple definition of nonalcoholic fatty liver disease is the build of fat in the liver. However, it also includes a large range of pathogenic cellular injuries. This includes inflammation, hepatic fibrosis, and cirrhosis. Most of these studies cannot differentiate if it is the caffeine or the coffee that causes reduced hepatic fibrosis. [1] Coffee consumption also reduces liver damage. If you don’t drink coffee already you shouldn’t start consuming coffee just because you have nonalcoholic liver disease. Consulting your doctor first is always the priority. [2]

Sources:

[1]Shen, Huafeng, et al. “Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-Analysis.” Therapeutic Advances in Gastroenterology, SAGE Publications, Jan. 2016, www.ncbi.nlm.nih.gov/pmc/articles/PMC4699270/.

[2] “Nonalcoholic fatty liver disease.” Mayo Clinic, Mayo Foundation for Medical Education and Research, 11 Aug. 2017, www.mayoclinic.org/diseases-conditions/nonalcoholic-fatty-liver-disease/diagnosis-treatment/drc-20354573

 

Share on FacebookShare on Google+Share on LinkedInTweet about this on TwitterEmail this to someonePrint this page